All articles by  

1. Sandoz to commercialise Shionogi’s Rizmoic in European markets

   Novartis unit Sandoz has entered an agreement to commercialise Japanese pharmaceutical company Shionogi’s drug Rizmoic (naldemedine) in the UK, Germany and…
   Read More…

   12 Apr
2. AstraZeneca’s Lynparza gets EC approval for breast cancer

   The European Commission (EC) has approved AstraZeneca drug Lynparza (olaparib) as a monotherapy to treat locally-advanced or metastatic breast cancer…
   Read More…

   11 Apr
3. Pfizer to use Concerto HealthAI technology for cancer treatments

   Pfizer has partnered with patient-centred research firm Concerto HealthAI to fast-track actionable patient insights for investigational and commercialised cancer therapies….
   Read More…

   11 Apr
4. Regeneron and Alnylam partner on eye and CNS disease therapies

   Regeneron Pharmaceuticals has formed an alliance with Alnylam Pharmaceuticals for the discovery, development and commercialisation of new RNA interference (RNAi)…
   Read More…

   10 Apr
5. FDA approves Amgen’s postmenopausal osteoporosis drug Evenity

   Amgen has received the US Food and Drug Administration (FDA) approval for Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women…
   Read More…

   10 Apr
6. Researchers develop new vaccine to teach immune system to attack cancer

   Researchers at Mount Sinai in the US have developed a new immunotherapy that can be injected directly into a tumour…
   Read More…

   9 Apr
7. ViiV’s two-drug regimen Dovato gets FDA approval for HIV-1

   ViiV Healthcare has received US Food and Drug Administration (FDA) approval for its single-tablet, two-drug regimen Dovato to treat human…
   Read More…

   9 Apr
8. Centene to fund Washington University’s personalised medicine research

   Healthcare services provider Centene has committed up to $100m to fund research at the Washington University School of Medicine in…
   Read More…

   9 Apr
9. Celgene seeks FDA approval for luspatercept to treat anaemia

   Celgene has submitted a biologics licence application (BLA) to the US Food and Drug Administration (FDA) seeking approval for luspatercept…
   Read More…

   8 Apr
10. Sanofi concludes option phase of rare disease alliance with Alnylam

    Sanofi has concluded the research and option phase of an RNAi therapeutics partnership in rare genetic diseases forged with biopharmaceutical…
    Read More…

    8 Apr